Alamar Biosciences
Biotechnology company developing next-generation proteomics technology with the NULISA platform for ultra-sensitive protein detection in precision medicine applications.
Location
Fremont, California, USA
Founded
2019
Investors
1
Categories
proteomics, diagnostics, biotech, precision-medicine
Notes
Alamar Biosciences is a biotechnology company revolutionizing proteomics with its proprietary NULISA (NUcleic acid-Linked Immuno-Sandwich Assay) platform. The technology enables ultra-sensitive and highly multiplexed protein detection from minimal sample volumes, addressing limitations of traditional immunoassays.
The NULISA platform combines antibody-based protein capture with DNA-based amplification and detection, achieving attomolar sensitivity while maintaining high specificity. Applications span drug development, biomarker discovery, and clinical diagnostics.
Team
- Shan X. Wang, Ph.D. - Co-founder & Chief Scientific Officer (Stanford Professor)
- LinkedIn: linkedin.com/in/shanwang
- Xiaohua Huang, Ph.D. - Co-founder
- Hongbo Zheng - CEO
Additional Research Findings
- NULISA platform enables detection of thousands of proteins simultaneously
- Attomolar sensitivity (10^-18 molar) with minimal sample input
- Technology originated from Stanford University research
- Focus on precision medicine and biomarker applications
- Partnered with major pharmaceutical companies for drug development
- Raised significant venture funding to scale commercial operations
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |